

Starting insulin in primary care

Readers can, if they choose, use this section to gain accreditation and feedback.

Section 1. Does your practice have guidelines for when to initiate insulin therapy in people with type 2 diabetes?

If yes, please give a brief outline of these three aspects:

- The circumstances under which insulin treatment is considered appropriate for a person with type 2 diabetes.
- How the insulin is initiated and by whom.
- The strategies that are in place for follow-up.

If no, please give a brief outline of how you manage people with type 2 diabetes requiring insulin.

Section 1d. Which of the following are available on prescription?

Needle clipping device	Y/N	NovoPen 3 pen injector	Y/N
Disposable needles for insulin pen injectors	Y/N	HumaPen pen injector	Y/N
Preloaded disposable insulin pens	Y/N	Glucagon/Glucogen	Y/N
Blood glucose testing meters	Y/N	Sharps boxes	Y/N
		Blood glucose testing strips for meters	Y/N

Section 2. This section is provided for readers wishing to refresh their knowledge. Readers may choose to defer reading this section until completion of the rest of the module.

Only a small proportion of people with diabetes require insulin. Type 1 diabetes (insulin-dependent diabetes) requires insulin from the outset and the clinical picture is such that this is usually initiated by the specialist hospital team. It is, however, becoming more common for insulin therapy to be initiated in primary care, through education and support, for those with type 2 (non-insulin-dependent) diabetes — in this case the people do not become ‘insulin dependent’ but ‘insulin-treated’.

Type 2 diabetes is on the increase, with doubling of numbers predicted between 1995 and 2010 (Amos et al, 1997). This increase will only be partly due to longevity. Other factors include rising levels of obesity in the population, less activity and insulin resistance.

Insulin resistance

Insulin resistance has been defined as an impairment in the ability of insulin to lower plasma glucose concentration, both by stimulating glucose uptake in insulin-sensitive tissues (predominantly skeletal muscle), and by inhibiting liver glucose production from glycogen or from gluconeogenic precursors (Yudkin and Tavare, 1999). In simple terms, insulin is released in response to glucose but fails to act at the cellular level. β -cells increase their output leading to compensatory hyperinsulinaemia and, eventually, β -cell failure. Blood sugar levels in people with type 2 diabetes will rise over time, in spite of their best endeavours (this demonstrates the progressive nature of the condition). Increases in medication then become desirable.

Progression may be halted by increasing activity levels and reducing surplus weight. Nolan (2001) postulated that the diabetogenic effects of obesity can be modulated by physical

activity, even in the absence of weight loss. He stated that a single bout of exercise could improve insulin sensitivity for up to 16 hours in type 2 patients. Multiple bouts had additive effects and also a beneficial effect on diabetic lipid profile.

Reducing complications

The long awaited results of the United Kingdom Prospective Diabetes Study (UKPDS, 1998) demonstrated that intensive blood glucose control by either sulphonylureas or insulin substantially decreased the risk of microvascular complications, particularly retinopathy and nephropathy. In order to achieve this, target levels for HbA_{1c} blood tests were set at 7%. This test, which gives an indication of blood sugar control over the preceding 2-3 months, is still not available in all laboratories and hence not to everyone in primary care. The authors also considered the effect of insulin on cardiovascular complications and reported no increase, concluding that the beneficial effect of an intensive glucose control with these agents outweighed the theoretical risks. It is now generally accepted that failure to control deteriorating blood sugar levels with oral medication necessitates treatment with insulin or a combination of insulin and oral medication.

Insulin

Insulin is the primary treatment for all patients with type 1 diabetes and for type 2 diabetes patients who are not adequately controlled by diet and/or oral hypoglycaemic agents. Ralph and DeFronzo (1999) suggested that insulin should be initial therapy for:

- Type 2 diabetes patients with a markedly elevated fasting

plasma glucose level (>15.6–16.7 mmol/l) and ketonuria

- Type 2 diabetes patients who, after discussing the options with the primary care physician, wish to receive insulin as initial therapy.
- Women with gestational diabetes mellitus whose disease is not controlled with diet alone. All oral agents are contraindicated during pregnancy.
- Type 2 diabetes patients with illness causing hyperglycaemia may need temporary insulin treatment.

The so-called ‘human’ insulin is not derived from humans as the name might suggest. Rather, genetic engineering technology is used to produce insulins identical to human insulin. Larger amounts of insulin can be produced this way, as compared with the traditional methods of producing pork or beef insulins. Some animal insulins are still available for those who prefer them but ‘human’ insulin is more widely used. Table 1 below provides more details on insulins.

Insulin in primary care

During the process of starting insulin therapy the person with diabetes needs to be well educated, whether the initiation is to take place in primary or secondary care, or by means of shared systems. They and their carers should be involved in ongoing discussions around:

- Possible side effects. Weight gain may be expected.
- Blood glucose monitoring if feasible. Involvement and participation of the patient is paramount. Lancets and testing strips are generally available on prescription. Meters are not.
- Injection technique: Issues include: To pinch or not to pinch? Which size needle? Dose alteration. Needle clipping devices are available on prescription, though sharps boxes are not. The following are prescribable: some pen injectors (including NovoPen 3), preloaded

pens, and pen needles.

- Rotation of sites, to prevent lipohypertrophy (fatty deposits through repeatedly injecting the same spot) which has detrimental effect on control.
- Prevention and treatment of hypos (this education is for carers too) including: effects of exercise and need for snacks; use of Hypostop gel or sugary alternative for conscious hypos; and Glucagon/Glucagen for severe hypos (both available on prescription).
- Eventual targets for control tailored to the individual. Interpretation of lab results.
- Disposal procedures for sharps and equipment. Local policy should be checked.
- Contact numbers for back-up from health professionals, including out of hours.
- Driving restrictions. These are changing rapidly at the moment. Diabetes UK or DVLA should be consulted.
- Sick day rules. The patient should be told never to stop insulin, but should be advised on what to do when ill. Blood sugars often rise when ill, even if not eating.
- Effects of exercise on control. Insulin absorption rate increases with exercise, especially if given in the leg before running.
- Drug interactions. β-blockers (may mask hypo symptoms), MAOIs, corticosteroids, diuretics (may raise sugar levels), alcohol (may exacerbate hypos).
- Diabetes UK. Regular updates.

Insulin companies provide educational material for people on insulin or converting to insulin.

Gaunt (1999) details one method of starting insulin in primary care but teamwork is vital for whatever method is chosen. All members of the team — GPs, dietitians, practice nurses, community nurses and health visitors especially — should be appropriately trained and receive support from

Preparation	Colour	Examples	Duration
Neutral insulin injection	Clear soluble (analogues) (insulin lispro)	NovoRapid (insulin aspart), Humalog	Very rapid acting. Can be given before, during or even just after a meal. Short duration. Peak action at 1/2 to 3 hours, depending on type.
	Clear soluble	Human Actrapid, Human Velosulin, Humulin S, Insuman Rapid	Short duration, to be taken 20–30 mins before meals. Peak action 1-4 hours.
Biphasic insulin Pre-mixes of soluble and isophane insulins.	Cloudy, needs mixing well	Humalog Mix Human Mixtard, Humulin ‘M’ range, Insuman Comb	Very rapid acting. Intermediate length of action. These are mixes with an intermediate onset and length of action depending on the mix used, e.g. Human Mixtard 30 (30iu actrapid + 70iu isophane) Humulin M2 (20iu Humulin S + 80iu isophane).
Isophane insulin	Cloudy	Human Insulatard, Humulin I, Hypurin Isophane Insuman Basal	Intermediate acting, onset of action 1-4 hours and may last up to 24 hours.
Insulin zinc suspension (mixed)	Cloudy	Human Monotard, Humulin Lente	Intermediate acting, onset of action 1-4 hours and may last up to 35 hours.
Insulin zinc suspension (crystalline)	Cloudy	Human Ultratard, Humulin Zn	Intermediate acting, onset of action 1-4 hours and may last up to 35 hours.

A useful chart detailing insulins and their actions can be found in *MIMS*. NB. This list is intended for educational purposes only and is not exhaustive.

Continued on page 19

Continued from page 14

the specialists at the hospital. Everyone should be aware of one another's responsibilities and a good system of recording information introduced to aid communication. The person with diabetes is the key player in that team.

Summary

The heavy burden of achieving tight glycaemic control is resulting in people with type 2 diabetes joining waiting lists to be converted to insulin treatment. Primary care teams are becoming involved in its initiation and/or follow-up. Additional resources need to be found to evaluate this role and strengthen the training possibilities. Perhaps the

imminent National Service Framework (NSF) will give us the tools to do the job. ■

Amos AF, McCarty DJ, Zimmet P (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. *Diabetic Medicine* 14(Suppl 5): S1-S85
 Gaunt F (1999) Managing the change to insulin therapy. *Practice Nurse* 18(1): 27-30
 Nolan J (2001) Primary defects in type 2 diabetes – the role of insulin resistance. *Practical Diabetes International* 18(1): S2-S3
 Ralph A, DeFronzo MD (1999) Pharmacologic Therapy for Type 2 Diabetes Mellitus. *Annals of Internal Medicine* 131(4): 281–305
 UKPDS (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 352: 837-853
 Yudkin, JS, Tavare, JM (1999) Insulin Resistance. *Practical Diabetes International* 16(5): S3

Section 3. Case studies

Case study 1

Jenny is a 62-year-old ex-teacher who lives alone. She has had type 2 diabetes for seven years, starting on diet alone and gradually increasing to her present treatment of metformin 850 tds and gliclazide 80mg bd. She is attending today for her annual review at the practice diabetes clinic. Her blood tests taken two weeks ago reveal: HbA_{1c} 8.7% (previously 8.3%), blood sugar 12.8mmol/l and raised lipid levels. She complains of thrush and of frequently getting up in the night.

Questions about case study 1

a) What advice about treatment would you discuss with Jenny?

b) You decide on initiation of insulin. Human Mixtard 30 is chosen. How would you explain how this insulin works to Jenny?

Case study 2

John is 43. He is overweight, as is the rest of his family. He works at the local garage and his mother, a patient of yours, has type 2 diabetes recently treated with insulin. His grandmother also had diabetes. He has no recent investigations in your records. He knows his glycaemic control is not good but has been putting off doing anything about it. You request an HbA_{1c} and the result is 9.8%. He denies any symptoms and his home blood sugar monitoring record is erratic but confirms that many results are in double figures. John is on maximum oral therapy. He is worried that he might need insulin.

Questions about case study 2

a) How would you address his concerns?

b) He realises that he might need insulin but expresses a fear of needles. What would you do?

Case study 3

Paula is a 54-year-old housewife who recently started on insulin. Her control had improved well but, over the last few days, her blood sugars have started to rise. This coincides with her catching the local flu bug that is going around. She has not been sick but is 'off her food'. She contacts you for advice.

Questions about case study 3

a) What do you suggest?

b) If she were vomiting what advice would you give her about her insulin and blood sugar monitoring?

EDUCATION MODULE No. 9: STARTING INSULIN IN PRIMARY CARE

Section 4. Think of three people with diabetes in your practice who have started insulin therapy and answer the questions below for each.

	Patient 1	Patient 2	Patient 3
a) What insulin was prescribed and why?			
b) Who provided the patient education for starting insulin?			
c) Which members of the team were involved and how?			
d) Has follow-up demonstrated improvement?			
e) What are the barriers, if any, to insulin management in your practice?			
f) What changes, if any, would you now like to make to your management of people requiring insulin to treat their diabetes?			

Section 5. After completing the above exercise, identify two or three key points, stating how this will influence your future practice.

1.
2.
3.

EDUCATION SUPPLEMENT APPLICATION FORM

Name.....	
Job title.....	
Address.....	
.....	
.....	
.....	Postcode.....
Telephone.....	Fax.....
GMC or UKCC registration number.....	
Has the programme been effective in meeting your needs?	Yes <input type="checkbox"/> No <input type="checkbox"/>
Comments.....	
.....	
Diabetes and Primary Care, SB Communications Group, 15 Mandeville Courtyard, 142 Battersea Park Road, LONDON SW11 4NB Tel. 020-7627 1510 Fax. 020-7627 1570	

DISTANCE LEARNING PACKAGE FOR THE PRIMARY CARE TEAM

How to complete the learning module...

Each issue of **Diabetes and Primary Care** contains a continuing education module. Each module carries 2 hours PGEA accreditation for GPs; nurses can complete the supplement to use towards their PREP requirements. Participants should be able to complete the supplement within 2 hours. This can then be submitted to the address on the application form for assessment and feedback. Certificates will be awarded to all health professionals completing the supplement to the required standard. No payment is required.

Standards to be achieved

To receive a certificate, the answers provided must meet the following criteria:

1. All questions within the supplement must be answered.

2. The minimum number of answers to individual questions should be given where specified.
3. Factual knowledge around the subject area, plus the case studies, will be compared with specimen answers for accuracy.
4. Questions around your own practice will be assessed for an adequate level of completion. Brief answers are acceptable.

The feedback will indicate one of two things:

- a) You have successfully completed the questions and will be awarded accreditation and a certificate.
- b) Your answers have been inadequate, and comments will be provided.

You will also receive a set of specimen answers against which to compare your own work.

Each module follows a standard format, relating to one area of diabetes care

- Section 1: Seeks information about your factual knowledge around the subject area
- Section 2: Provides factual information to enable you to revise and refresh your existing knowledge (this section will contain no questions for you to answer)
- Section 3: Presents two or three case studies to provide you with an opportunity to apply your knowledge to different patient scenarios
- Section 4: Invites you to answer questions about the treatment of a number of patients within your practice around the subject area
- Section 5: Asks how completion of the supplement will influence your future practice